Janus kinase inhibitors and biologics for treatment of livedoid vasculopathy: a systematic review
Purpose: Livedoid vasculopathy (LV) is a chronic microvascular thrombosis disorder with an unclear pathogenesis, potentially involving hypercoagulability and inflammation. This systematic review aims to evaluate the efficacy and safety of Janus kinase (JAK) inhibitors and biologics in the treatment...
Saved in:
Main Authors: | Yu Liu, Tingting Li, Wei Shi |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2025-12-01
|
Series: | Journal of Dermatological Treatment |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2025.2451804 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Baricitinib Successfully Treated a Teenager with Refractory Livedoid Vasculopathy: A Case Report and Literature Review
by: Liu C, et al.
Published: (2025-02-01) -
Livedoid vasculopathy with mononeuritis multiplex associated with protein S deficiency mimicking systemic vasculitis
by: Vikramraj K Jain, et al.
Published: (2019-01-01) -
Increased risk of Pneumocystis jirovecii colonization in rheumatoid arthritis patients on biologics and Janus kinase inhibitor
by: Ya-Chun Huang, et al.
Published: (2025-02-01) -
Janus kinase inhibitor treatment for inflammatory diseases: excess or no excess risk of venous thromboembolism?
by: Yachar Dawudi, et al.
Published: (2025-01-01) -
Role of Janus Kinase inhibitors in the management of pulmonary involvement due to Long COVID-19 disease: A case control study
by: Pawan Kumar Singh, et al.
Published: (2023-07-01)